Allergan plc Share Price





Delayed Nyse 5-day change 1st Jan Change
- USD -.--% Intraday chart for Allergan plc +1.73% +0.97%
Sales 2018 15.79B 1,221B Sales 2019 16.09B 1,245B Capitalization 62.76B 4,855B
Net income 2018 -5.1B -394B Net income 2019 -5.27B -408B EV / Sales 2018 4.24 x
Net Debt 2018 21.89B 1,694B Net Debt 2019 17.3B 1,339B EV / Sales 2019 4.98 x
P/E ratio 2018
-8.76 x
P/E ratio 2019
-11.9 x
Employees -
Yield 2018
Yield 2019
Free-Float 99.9%
More Fundamentals * Estimated data
Dynamic Chart
Allergan Aesthetics Debuts Alle Payment Plans CI
Allergan Aesthetics Announces the U.S. FDA Approval of JUVEDERM VOLUMA XC for Injection in the Temple Region to Improve Moderate to Severe Temple Hollowing in Adults over the Age of 21 CI
Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of Onabotulinumtoxina for the Treatment of Platysma Prominence CI
Allergan Aesthetics Announces the Journal of Cosmetic Dermatology Publishes Data Demonstrating Patient Satisfaction with Natural-Looking Outcomes Following Treatment with OnabotulinumtoxinA (BotoX®? Cosmetic) CI
Allergan plc Announces U.S. FDA Approval of SKINVIVE™ by JUVÉDERM® CI
Allergan Aesthetics Announces the Highly Anticipated National Launch of Juvéderm® Volux™ Xc CI
Allergan Aesthetics Announces the Launch of the Long-Awaited SkinMedica Even & Correct Collection CI
Allergan Aesthetics to Present Data from Its Leading Aesthetic Portfolio At the 2022 American Society for Dermatologic Surgery Meeting CI
Allergan Aesthetics Announces the Launch of SkinMedica Firm & Tone Lotion for Body CI
FDA Approves JUVÉDERM® VOLUX™ XC for Improvement of Jawline Definition CI
Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics CI
PatientFi Expands Partnership with Allergan Aesthetics CI
Allergan plc completed the acquisition of Soliton, Inc. for approximately $570 million. CI
Allergan Aesthetics to Present Data from its Aesthetic Portfolio at the 2021 American Society for Dermatologic Surgery Virtual Meeting CI
Allergan, an AbbVie Company, to Present New Data on Investigational AGN-190584 for the Treatment of Presbyopia CI
More news
Managers TitleAgeSince
Director of Finance/CFO 54 30/11/16
President 53 07/05/20
Members of the board TitleAgeSince
President 53 07/05/20
Director/Board Member - 07/05/20
Director/Board Member - 07/05/20
More insiders
Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.
More about the company